Crescent Biopharma Inc (CBIO)

$10.90 +0.28 (2.64%)
Market Cap 143.79M
Revenue (ttm) 10.84M
Net Income (ttm) -153.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,420.11%
Debt to Equity Ratio 0.00
Volume 184,500
Avg Vol 192,392
Day's Range N/A - N/A
Shares Out 13.89M
Stochastic %K 29%
Beta 1.31
Analysts Strong Sell
Price Target $29.29

Company Profile

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 460 5595
Address:
300 Fifth Avenue, Waltham, United States
slick3333
slick3333 Mar. 19 at 1:34 AM
$CBIO a bottomless pit coming to a stick near you
0 · Reply
newyork1979
newyork1979 Mar. 18 at 11:59 PM
TAOP could easily 3X from here - 900k FLoat with no dilution - Robotics / AI merger coming with a company that has HUGE customers like mcdonalds/KFC/Starbucks - TAOP is only valued around $12M , very undervalued. - Shorts are trapped and will be forced to buyback all their shares which will cause a Mother of all short squeezes. $ASNS $SUNE $ELA $RMSG $CBIO WW
0 · Reply
CantNameThatTune
CantNameThatTune Mar. 5 at 11:40 AM
$IBO Thinking about $CBIO that went up 500%+ recently. It was touted for its advancements with its EpiGen CHD and Precision CHD AI driven something or other for which they have yet to generate a single dollar of sales. On this side you have IBO merging with Dr. Ashley Medicine that is currently producing/administering 300 million doses per year for various orphan diseases and CDMOs. I would have thought $BILLIONS in sales would make a stock go higher more than a company with no sales.
0 · Reply
Stock__Hunter
Stock__Hunter Feb. 25 at 7:57 PM
$CBIO charts never ever lie, but people on these boards do and it's on purpose to take your money Been OG for 20+ yrs ... seen it all
0 · Reply
slick3333
slick3333 Feb. 22 at 6:21 PM
$CBIO too much pending and too early on for any significant upside risk reward definitely not here wait for the big dump and dilution and re evaluate
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 1:58 AM
$CBIO Current Stock Price: $11.63
0 · Reply
GSP
GSP Feb. 18 at 6:02 PM
$CBIO getting some volume here.
1 · Reply
BullButter23
BullButter23 Feb. 18 at 12:53 PM
$CBIO 🚀🧨🙌🏼 https://www.benzinga.com/pressreleases/26/02/g50682132/crescent-biopharma-announces-first-patient-dosed-in-ascend-phase-12-clinical-trial-of-cr-001-for-t
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 2:47 PM
$CBIO RSI: 16.76, MACD: -0.8087 Vol: 1.69, MA20: 10.56, MA50: 11.65 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Estimize
Estimize Feb. 16 at 1:03 PM
Wall St is expecting -1.08 EPS for $CBIO Q1 [Reporting 04/30 BMO] http://www.estimize.com/intro/cbio?chart=historical&metric_name=eps&utm_c
0 · Reply
Latest News on CBIO
Crescent Biopharma Announces Grants of Inducement Awards

Mar 6, 2026, 4:15 PM EST - 15 days ago

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 26, 2026, 7:30 AM EST - 23 days ago

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Crescent Biopharma to Present at March Investor Conferences

Feb 23, 2026, 7:30 AM EST - 26 days ago

Crescent Biopharma to Present at March Investor Conferences

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

Feb 18, 2026, 7:30 AM EST - 4 weeks ago

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:30 AM EST - 6 weeks ago

Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

Jan 5, 2026, 7:00 AM EST - 2 months ago

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

Dec 4, 2025, 6:35 AM EST - 3 months ago

Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

Dec 4, 2025, 6:30 AM EST - 3 months ago

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:30 AM EST - 4 months ago

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Crescent Biopharma to Present at November Investor Conferences

Nov 5, 2025, 7:30 AM EST - 4 months ago

Crescent Biopharma to Present at November Investor Conferences

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Nov 4, 2025, 9:05 AM EST - 4 months ago

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Crescent Biopharma to Present at September Investor Conferences

Aug 28, 2025, 7:30 AM EDT - 7 months ago

Crescent Biopharma to Present at September Investor Conferences

Crescent Biopharma: Chasing The Summit Hype

Aug 18, 2025, 11:33 AM EDT - 7 months ago

Crescent Biopharma: Chasing The Summit Hype

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 31, 2025, 7:34 AM EDT - 8 months ago

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

Jul 8, 2025, 7:30 AM EDT - 9 months ago

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

Jun 16, 2025, 7:00 AM EDT - 9 months ago

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

Jun 5, 2025, 4:01 PM EDT - 10 months ago

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 7:30 AM EDT - 10 months ago

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

May 16, 2025, 1:55 PM EDT - 11 months ago

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

Crescent Biopharma Appoints David Lubner to Board of Directors

Apr 28, 2025, 7:30 AM EDT - 11 months ago

Crescent Biopharma Appoints David Lubner to Board of Directors

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

Apr 3, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

Mar 5, 2025, 11:20 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

CMRX

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

Nov 6, 2024, 7:00 AM EST - 1 year ago

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

Oct 29, 2024, 11:47 AM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

PFIE

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Oct 29, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

Oct 29, 2024, 6:30 AM EDT - 1 year ago

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

Jul 25, 2024, 9:00 AM EDT - 1 year ago

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Jun 4, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

May 29, 2024, 4:01 PM EDT - 1 year ago

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript

May 9, 2024, 3:17 PM EDT - 2 years ago

GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

May 6, 2024, 6:00 AM EDT - 2 years ago

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

GlycoMimetics: Is No News Bad News?

Apr 30, 2024, 7:42 AM EDT - 2 years ago

GlycoMimetics: Is No News Bad News?

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 25, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 10:27 AM EDT - 2 years ago

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

Mar 27, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

GlycoMimetics Can Become A Game Changer In Blood Cancers

Mar 21, 2024, 5:47 PM EDT - 2 years ago

GlycoMimetics Can Become A Game Changer In Blood Cancers

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

Mar 13, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

Feb 26, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Feb 12, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

Jan 30, 2024, 1:04 PM EST - 2 years ago

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

Jan 4, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Dec 10, 2023, 12:00 PM EST - 2 years ago

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

Nov 9, 2023, 7:00 AM EST - 2 years ago

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript

Nov 3, 2023, 12:24 PM EDT - 2 years ago

GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Nov 3, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

Oct 30, 2023, 12:00 PM EDT - 2 years ago

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

slick3333
slick3333 Mar. 19 at 1:34 AM
$CBIO a bottomless pit coming to a stick near you
0 · Reply
newyork1979
newyork1979 Mar. 18 at 11:59 PM
TAOP could easily 3X from here - 900k FLoat with no dilution - Robotics / AI merger coming with a company that has HUGE customers like mcdonalds/KFC/Starbucks - TAOP is only valued around $12M , very undervalued. - Shorts are trapped and will be forced to buyback all their shares which will cause a Mother of all short squeezes. $ASNS $SUNE $ELA $RMSG $CBIO WW
0 · Reply
CantNameThatTune
CantNameThatTune Mar. 5 at 11:40 AM
$IBO Thinking about $CBIO that went up 500%+ recently. It was touted for its advancements with its EpiGen CHD and Precision CHD AI driven something or other for which they have yet to generate a single dollar of sales. On this side you have IBO merging with Dr. Ashley Medicine that is currently producing/administering 300 million doses per year for various orphan diseases and CDMOs. I would have thought $BILLIONS in sales would make a stock go higher more than a company with no sales.
0 · Reply
Stock__Hunter
Stock__Hunter Feb. 25 at 7:57 PM
$CBIO charts never ever lie, but people on these boards do and it's on purpose to take your money Been OG for 20+ yrs ... seen it all
0 · Reply
slick3333
slick3333 Feb. 22 at 6:21 PM
$CBIO too much pending and too early on for any significant upside risk reward definitely not here wait for the big dump and dilution and re evaluate
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 1:58 AM
$CBIO Current Stock Price: $11.63
0 · Reply
GSP
GSP Feb. 18 at 6:02 PM
$CBIO getting some volume here.
1 · Reply
BullButter23
BullButter23 Feb. 18 at 12:53 PM
$CBIO 🚀🧨🙌🏼 https://www.benzinga.com/pressreleases/26/02/g50682132/crescent-biopharma-announces-first-patient-dosed-in-ascend-phase-12-clinical-trial-of-cr-001-for-t
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 2:47 PM
$CBIO RSI: 16.76, MACD: -0.8087 Vol: 1.69, MA20: 10.56, MA50: 11.65 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Estimize
Estimize Feb. 16 at 1:03 PM
Wall St is expecting -1.08 EPS for $CBIO Q1 [Reporting 04/30 BMO] http://www.estimize.com/intro/cbio?chart=historical&metric_name=eps&utm_c
0 · Reply
Magic8BallResponse
Magic8BallResponse Feb. 13 at 8:43 PM
$CBIO Late to the party and late to the party. Oh and late to the party. Keep an eye on institutions that joined late to the party.
0 · Reply
lyonsa14
lyonsa14 Feb. 13 at 8:29 PM
$CBIO My main concern is there are several large pharma companies with similar programs that are in phase 3 development. Since CBIO is only in phase 1 development, I’m concerned they’re a bit late with likely a “me too” drug. I’m less concerned about dilution in the short run since they just raised capital at the end of last year. A key question: are they going to develop this agent in tumor types that the other companies are not currently targeting?
0 · Reply
Magic8BallResponse
Magic8BallResponse Feb. 13 at 7:24 PM
$CBIO Trials are expensive.
0 · Reply
slick3333
slick3333 Feb. 12 at 10:09 PM
$CBIO ouchie wow wow new all time low leggo
1 · Reply
slick3333
slick3333 Feb. 9 at 11:18 PM
$CBIO long forgotten….
0 · Reply
ProfProfit
ProfProfit Jan. 31 at 2:44 AM
$CBIO due to go back up???
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 28 at 2:29 PM
$CBIO Current Stock Price: $11.24
0 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Jan. 27 at 5:51 PM
$CBIO Clinical thesis is strictly data-driven. Targeting HR 0.51 vs $MRK Keytruda (HR 1.0) in 1L NSCLC. Proxy data confirms mPFS jump from 5.8m to 11.1m. Key differentiator: Efficacy in Squamous tumors where $RHHBY Avastin failed. This is a SOC replacement play, not an adjuvant play. $AZN $BMY Read more: www.clinicaltrialsdaily.com/cr-001-skb118-nsclc-standard-care-disruption/
1 · Reply
Love_To_Learn
Love_To_Learn Jan. 21 at 11:33 PM
$APVO $CBIO need u 2 both shortly few things* as marc has chosen what he wants on al matters now not just his personal and that will b respected *
0 · Reply
Glendadunn84
Glendadunn84 Jan. 7 at 2:24 PM
$CBIO you should be ready.
0 · Reply
Steganography
Steganography Dec. 26 at 1:34 PM
$CBIO Price action signals that reliability now matters more than headline momentum. Governance alignment should reduce uncertainty over time. Sustained traction could validate the investment case. Patience is reasonable — but it must be earned.
0 · Reply